surmount 1 tirzepatide 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers Gastrointestinal tolerability and weight reduction

2021;44(Suppl 1):12550

NAD+ and sirtuins in aging and healthspan

Ross SA

Its possible that youve received compounded semaglutide, which has its own potential risks

Misoprostol, an FDA-approved prostaglandin analog, prevents NSAID-induced ulcers with a number needed to treat (NNT) of approximately 8 based on the MUCOSA trial 12

Supply Planning Each vial provides 25 doses regardless of reconstitution choice (2.5 mL 0.1 mL = 5 mL 0.2 mL = 25): Weeks 1-4 (daily): 28 doses Weeks 5-8 (5x weekly): 20 doses Weeks 9-12 (2-3x weekly): 8-12 doses Total: 56-60 doses, usually 3 vials for a 12-week protocol Supporting Factors: Diet, Vitamins, Hydration, Sleep Optional adjuncts: Red light therapy (630-670 nm): 10-20 min daily Microneedling: Every 3-4 weeks during Phase 2 When Progress Stalls during a GLOW / KLOW Protocol Each stall pattern has a different fix, and the signal is what distinguishes them not the impulse to push harder